5vh4

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
m (Protected "5vh4" [edit=sysop:move=sysop])
Line 1: Line 1:
-
'''Unreleased structure'''
 
-
The entry 5vh4 is ON HOLD
+
==Crystal structure of Fab fragment of anti-TNFa antibody infliximab in an I-centered orthorhombic crystal form==
 +
<StructureSection load='5vh4' size='340' side='right' caption='[[5vh4]], [[Resolution|resolution]] 2.00&Aring;' scene=''>
 +
== Structural highlights ==
 +
<table><tr><td colspan='2'>[[5vh4]] is a 4 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=5VH4 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5VH4 FirstGlance]. <br>
 +
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene>, <scene name='pdbligand=NAD:NICOTINAMIDE-ADENINE-DINUCLEOTIDE'>NAD</scene></td></tr>
 +
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[5vh3|5vh3]], [[5vh5|5vh5]]</td></tr>
 +
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=5vh4 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=5vh4 OCA], [http://pdbe.org/5vh4 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=5vh4 RCSB], [http://www.ebi.ac.uk/pdbsum/5vh4 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=5vh4 ProSAT]</span></td></tr>
 +
</table>
 +
<div style="background-color:#fffaf0;">
 +
== Publication Abstract from PubMed ==
 +
Aggregation and self-association in protein-based biotherapeutics are critical quality attributes that are tightly controlled by the manufacturing process. Aggregates have the potential to elicit immune reactions, including neutralizing anti-drug antibodies, which can diminish the drug's efficacy upon subsequent dosing. The structural basis of reversible self-association, a form of non-covalent aggregation in the native state, is only beginning to emerge for many biologics and is often unique to a given molecule. In the present study, crystal structures of the infliximab (Remicade) Fc and Fab domains were determined. The Fab domain structures are the first to be reported in the absence of the antigen (i.e., tumor necrosis factor), and are consistent with a mostly rigid complementarity-determining region loop structure and rotational flexibility between variable and constant regions. A potential self-association interface is conserved in two distinct crystal forms of the Fab domain, and solution studies further demonstrate that reversible self-association of infliximab is mediated by the Fab domain. The crystal structures and corresponding solution studies help rationalize the propensity for infliximab to self-associate and provide insights for the design of improved control strategies in biotherapeutics development.
-
Authors: Mayclin, S.J., Edwards. T.E., Lerch, T.F., Conlan, H., Sharpe, P.
+
Infliximab crystal structures reveal insights into self-association.,Lerch TF, Sharpe P, Mayclin SJ, Edwards TE, Lee E, Conlon HD, Polleck S, Rouse JC, Luo Y, Zou Q MAbs. 2017 Apr 19:0. doi: 10.1080/19420862.2017.1320463. PMID:28421849<ref>PMID:28421849</ref>
-
Description: Crystal structure of Fab fragment of anti-TNFa antibody infliximab in an I-centered orthorhombic crystal form
+
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
-
[[Category: Unreleased Structures]]
+
</div>
-
[[Category: Mayclin, S.J]]
+
<div class="pdbe-citations 5vh4" style="background-color:#fffaf0;"></div>
-
[[Category: Sharpe, P]]
+
== References ==
-
[[Category: Edwards. T.E]]
+
<references/>
 +
__TOC__
 +
</StructureSection>
[[Category: Conlan, H]]
[[Category: Conlan, H]]
-
[[Category: Lerch, T.F]]
+
[[Category: Edwards, T E]]
 +
[[Category: Lerch, T F]]
 +
[[Category: Mayclin, S J]]
 +
[[Category: Sharpe, P]]
 +
[[Category: Anti-tnfa]]
 +
[[Category: Antibody]]
 +
[[Category: Biosimilar]]
 +
[[Category: Fab]]
 +
[[Category: Immune system]]
 +
[[Category: Infliximab]]
 +
[[Category: Tnfa]]

Revision as of 13:01, 4 May 2017

Crystal structure of Fab fragment of anti-TNFa antibody infliximab in an I-centered orthorhombic crystal form

5vh4, resolution 2.00Å

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools